Biodesix BDSX Q2 2025 Earnings Call Transcript

Biodesix reported Q2 revenue of $20.0 million, up 12% year over year, with lung diagnostics revenue rising 8% to $17.9 million and Development Services revenue jumping 53% to $2.1 million. Gross margin improved 150 bps to 80%, while management maintained full-year revenue guidance of $80 million to $85 million and reiterated expectations for adjusted EBITDA positivity in Q4. Offsetting the positive trends, the company still posted an $11.5 million net loss and a $7.2 million adjusted EBITDA loss.

Analysis

BDSX is showing the kind of early operating inflection that can matter more than headline EPS: the commercial engine is starting to compound off a larger rep base, while digital ordering and on-site blood draws are quietly improving conversion economics. The second-order effect is that each additional rep is not just adding volume, but also raising the productivity of the installed pulmonology base by pulling primary care into the referral loop, which should reduce leakage and improve repeat ordering over time.

The market is likely underestimating how much of the near-term upside is self-help rather than macro or regulatory. Management has effectively insulated the 2025/2026 forecast from the delayed HEDIS decision, which removes a feared catalyst, but also creates a cleaner setup: if PCP adoption continues to rise from the current low-single-digit mix, there is incremental revenue with no reliance on policy tailwinds. The main bull case is not one big event; it is a sequence of small execution wins that can push the business over the fixed-cost leverage hump into Q4 EBITDA positivity.

The key risk is that this is still a capital-intensive model with limited margin for commercial missteps. A 10%+ revenue miss, slower rep ramp, or lower-than-expected development-services cadence would likely push out breakeven and re-open dilution/financing concerns within 2-3 quarters. Another subtle risk is channel conflict: if pulmonologists view primary-care expansion as cannibalizing their role, the referral-network strategy could slow before it reaches scale.

Key Decisions for Investors

• Long BDSX for a 3-6 month tactical trade into Q4 EBITDA inflection; target a rerating if the market begins to price a credible path to cash-flow breakeven, but keep a tight stop if PCP mix stalls below ~10% or rep productivity slips.
• Buy BDSX call spreads expiring after the next two quarters to express upside on operating leverage while limiting dilution risk; best setup is a moderate delta structure rather than outright equity given financing overhang.
• Pair trade: long BDSX / short a slower-growth diagnostics peer with weaker commercial leverage; this isolates execution alpha around rep-driven volume growth and digital-ordering conversion.
• If already long, hedge with a small put spread into the next earnings cycle; the binary risk is not product failure, but a pause in sales-force productivity that could delay EBITDA positivity by 1-2 quarters.
• For more risk-averse accounts, wait for confirmation: add only after a month of evidence that primary-care ordering remains above the post-pilot step-up and development-services contract backlog continues to convert.